| 1 |
26473751 | VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. | 2016 Jan |
3 |
| 2 |
25385260 | A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. | 2015 Feb |
1 |
| 3 |
25762693 | VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. | 2015 May |
3 |
| 4 |
24818516 | Selective JAK inhibitors in development for rheumatoid arthritis. | 2014 Aug |
1 |
| 5 |
23055694 | Kinase inhibitors: a new class of antirheumatic drugs. | 2012 |
1 |